title: Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.
abstract: OBJECTIVE
  This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia.
  
  
  METHODS
  This study used data from a three-year, prospective, nonrandomized, noninterventional, multisite study of schizophrenia. Participants initiated on oral haloperidol or fluphenazine (N=202) were compared with those initiated on haloperidol or fluphenazine in depot formulation (N=97) on time to all-cause discontinuation for one year after initiation, by using Kaplan-Meier survival analysis, a Cox proportional hazards regression model, and propensity score-adjusted bootstrap resampling methods.
  
  
  RESULTS
  Compared with participants treated with the oral formulation, those treated with depot first-generation antipsychotics had a significantly longer mean time to all-cause medication discontinuation and were twice as likely to stay on the medication.
  
  
  CONCLUSIONS
  In the usual care of schizophrenia, treatment with first-generation antipsychotics in depot formulation appears to be associated with longer time to all-cause medication discontinuation compared with oral formulation of the same medication.
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA.
authors.forename: Baojin
authors.initials: B
authors.lastname: Zhu
authors.forename: Haya
authors.initials: H
authors.lastname: Ascher-Svanum
authors.forename: Lizheng
authors.initials: L
authors.lastname: Shi
authors.forename: Douglas
authors.initials: D
authors.lastname: Faries
authors.forename: William
authors.initials: W
authors.lastname: Montgomery
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Marder
mesh_terms: D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004334:Drug Administration Schedule; D005476:Fluphenazine / Q000008:administration & dosage / Q000627:therapeutic use*; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D053208:Kaplan-Meier Estimate; D011446:Prospective Studies; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D006220:Haloperidol; D005476:Fluphenazine